97
Participants
Start Date
March 13, 2015
Primary Completion Date
December 13, 2016
Study Completion Date
November 21, 2017
CC-486
Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
Fulvestrant
Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
GasthuisZusters Antwerpen, Wilrijk
Clinique Sainte Elisabeth - Service d'Oncologie, Namur
Grand Hopital de Charleroi, Charleroi
Hospital Universitario Vall D Hebron, Barcelona
AZ Groeninge, Kortrijk
Clinical Research Alliance, New York
Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Piemonte
Complejo Universitario La Coruna, A Coruña
Ospedale San Raffaele S.r.l., Milan
Istituto Nazionale Dei Tumori, Milan
IEO- Istituto Europeo di Oncologia, Milan
Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg
Hamatologisch Onkologische Praxis Eppendorf, Hamburg
Hospital General Gregorio Maranon, Madrid
Hospital Ramon y Cajal, Madrid
Hospital Clinico Universitario Virgen de La Victoria, Málaga
Institut Bergonie, Borddeaux Cedex
Florida Cancer Specialists, West Palm Beach
Policlinico S. Orsola - Malpighi, Bologna
Hospital Virgen del Rocio, Seville
Arcispedale Santa Maria Nuova, Reggio Emilia
Centre Rene Gauducheau Centre de Lutte Contre Le Cancer Nantes Atlantique, Saint-Herblain
Henry Ford Health System, Detroit
Centre Regional de lutte contre le cancer Paul Papin, Angers
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz
University of Kansas Hospital, Westwood
Highlands Oncology Group, Fayetteville
Hopital Pitie Salpetriere, Paris
TU München - Klinikum rechts der Isar, München
Ironwood Cancer and Research Center, Chandler
Virginia G Piper Cancer Center, Scottsdale
Medical Oncology Associates, Spokane
Policlinico Umberto I, Roma
Policlinico Universitario A Gemelli, Roma
Hospital del Mar, Barcelona
Lead Sponsor
Celgene
INDUSTRY